SCHEMBL23745554

SCHEMBL23745554

CCCC(C)(C)c1ccc(N2CCCCC2)nc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.47
▸ CYP1A2 P05177 1/20 0.40
▸ GRM2 Q14416 1/20 0.38
▸ CXCR3 P49682 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ MAOB P27338 4/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ NSD2 O96028 1/20 0.34
▸ CRHBP P24387 1/20 0.34
▸ CRHR2 Q13324 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ CHRM4 P08173 2/20 0.33
▸ RXRA P19793 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23745556 0.82 ADRB2 (0.50) ADRB2CYP1A2GRM2CNR2MAOB
SCHEMBL12780912 0.76 ADRB2 (0.70) ADRB2CYP1A2CXCR3CNR2MAOB
SCHEMBL23779626 0.76 ADRB2 (0.70) ADRB2CYP1A2CXCR3CNR2MAOB
SCHEMBL21719003 0.71 XPO1 (0.32) —
SCHEMBL21718998 0.69 PDE2A (0.31) ALDH1A1PDE10A
SCHEMBL906077 0.65 ADRB2 (0.97) ADRB2CYP1A2CXCR3ALDH1A1MAPK1
SCHEMBL29388809 0.65 ADRB2 (0.97) ADRB2CYP1A2CXCR3ALDH1A1MAPK1
SCHEMBL23779477 0.64 ADRB2 (0.47) ADRB2CYP1A2CNR2ALDH1A1MAPT
SCHEMBL21181781 0.64 ADRB2 (0.47) ADRB2CYP1A2CNR2ALDH1A1MAPT
SCHEMBL22062292 0.64 TRPV1 (0.41) CNR2ALDH1A1MAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246115-A1 ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF BIOIMICS AB (SE) 2021-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246115-A1 ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF FDPS, FPR1, F12 ADRB2 4261/4885CYP1A2 331/4885GRM2 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback